A carregar...
Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
PURPOSE: The regimen including concurrent docetaxel, doxorubicin, and cyclophosphamide (TAC) has been categorized as an important risk factor for febrile neutropenia (FN). This comparative study examined the clinical impact of long-acting granulocyte colony-stimulating factor (G-CSF) (pegfilgrastim)...
Na minha lista:
| Publicado no: | J Breast Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Korean Breast Cancer Society
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7604368/ https://ncbi.nlm.nih.gov/pubmed/33154827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4048/jbc.2020.23.e52 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|